Bristol Myers' hope for a third Reblozyl OK delayed by three months
Bristol Myers Squibb was supposed to find out by this Sunday if the FDA was OK with a third approval for its Celgene-acquired, Acceleron-partnered anemia drug Reblozyl.
But “a major amendment” is putting a bump in those plans.
The Big Pharma will have to wait another three months, possibly as far out as June 27, to see if the agency will greenlight a supplemental nod. Bristol Myers wants Reblozyl — one of four drugs that the company anticipates could eventually rack up $4 billion in revenue per year — to also be a treatment for anemia in adults with non-transfusion-dependent (NTD) beta thalassemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
